Skip to content

Author

Chagaleti Bharath Kumar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Machine learning-guided discovery of a novel natural CDK7 inhibitor for triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited targeted therapeutic options; while sacituzumab govitecan and PARP inhibitors (for BRCA-mutated TNBC) have received regulatory approval in specific patient subgroups, the majority of TNBC patients continue to lack effective targete...

Chagaleti Bharath Kumar, Gandi Sony Pears · 0 citations
Aug 2026

Synthesis and in silico evaluation of novel hybrid 1,4-benzothiazine-1,1-dioxide-bis(1,2,3-triazole) derivatives as potential SRC kinase inhibitors via 1,3-dipolar cycloaddition.

Herein, we report the synthesis of new 1,4-benzothiazine-1,1-dioxide derivatives bearing bis(1,2,3-triazole) moieties via click chemistry in good to high yields and fully characterized by 1H NMR, 13C NMR and HRMS. The compounds were evaluated using a combined in silico approach, including physicochemical, pharmacokinet...

Ezaddine Irrou, Chagaleti Bharath Kumar, Y. Riadi et al. · 0 citations
Aug 2026

One-Pot Synthesis of Naphthalen-2-Thiazolidinones as Potential Breast Cancer Therapeutics: An Integrative Approach Using Network Pharmacology, Biomolecular Simulations and in Vitro Evaluation

Overall, the moderate promising leads of NT1 and NT9 emerged with dual-target potential for breast cancer, supporting further optimization and preclinical assessment.

C. N. Babu, Mazin Aboobaida Abdalla Abdelaziz, N. Nizamuddin et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.